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ABSTRACT
Background. Management of patients with oncohaematological disorders such as monoclonal gammopathy of
undetermined significance (MGUS) is a frequent problem in pre-transplant work-up. Insights on disease progression and
long-term functional outcomes are still lacking in this setting.
Methods. This was a retrospective analysis on all patients with MGUS who underwent kidney transplant (KT) at our centre
between 1 January 2000 and 31 December 2017 (cases, n¼65). Patients were matched with a control group (KTs with similar
characteristics but without history of haematological disease, controls, n¼1079). Primary endpoints were graft and patient
survival; secondary endpoints were causes of graft failure, patient death, occurrence of allograft rejection, post-transplant
neoplasia (not correlated to previous disorder) and/or infectious episodes.
Results. The MGUS and control groups had a similar mean age [60 (29–79) versus 55.2 (19.3–79.5) years, respectively] and
percentage of males (69.2% versus 64.6%, respectively). Median follow-up time since KT was 3.5 years (0–14) in cases and
8.3 years (0–14.9) in controls. All MGUS patients underwent KT following extensive multidiscliplinary investigations. No
differences were found between cases and controls regarding patient and graft survival or post-transplant complications
except for lower incidence of infections (58.7% versus 69.8%, P¼0.019) and increased use of mTOR inhbitors (30.3% versus
14.7%, P¼0.001) in MGUS. MGUS isotype did not influence graft and patient survival. The absence of difference in patients
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and graft survival was also confirmed in an adjunctive analysis where MGUS were compared with controls (ratio 1:2)
matched for recipient age, gender, number of transplantations and transplant period.
Conclusion. Patients with MGUS may undergo KT without significantly increased risks of complications, provided that
appropriate diagnostic procedures are carefully followed. Multidiscipline-based studies are crucial for establishing well
designed pre- and post-transplant protocols for the best management of patients with coexisting MGUS and end-stage
renal disease.
Keywords: graft function, graft survival, immunosuppression, kidney transplantation, mTOR, multiple myeloma, survival
analysis
INTRODUCTION
Chronic kidney disease (CKD) is a worldwide public health prob-
lem with a continuously increasing prevalence of end-stage re-
nal disease (ESRD) despite a stabilized incidence [1]. Kidney
transplant (KT) currently remains the best renal replacement
therapy. Although the risk of rejection has progressively de-
creased over time due to improvements of immunosuppressive
therapies, the prolonged exposure to such therapies has pro-
duced an increase in infectious and neoplastic risks, with inci-
dence of cancer three to five times higher than in general
population [2]. Patients therefore need to be carefully evaluated
before KT.
Due to progressive lengthening of the average life expec-
tancy and improvements in therapies and survival rate of many
neoplastic diseases, oncohaematological disorders are now one
of the most frequent conditions to deal with in pre-transplant
work-up. In particular, the co-existence of monoclonal gamm-
opathy of undetermined significance (MGUS) is a rather fre-
quent finding. Despite the increasing incidence of this
condition, information regarding the long-term outcome of
MGUS patients following KT is still scarce. So far, most studies
on MGUS and KT have dealt with case reports or case series
with limited sample size, in the absence of comparative analy-
sis with adequate control groups [3–6]. Indeed, exhaustive spe-
cific indications are lacking in international guidelines about
pre-transplant and post-transplant management of patients
with MGUS unrelated to the underlying ESRD [7–12].
In this study, a retrospective analysis has been performed in
patients undergoing KT with a previous diagnosis of MGUS. The
study aimed to evaluate whether the presence of MGUS might
affect overall and organ survival. The behaviour of the haema-
tological disorder and the incidence of post-transplant compli-
cations following KT were investigated as well. Moreover, it has
been possible to compare the MGUS series with a control KT




The study has included 2034 KTs, from either deceased or living
donors, performed at Turin University Renal Transplant Centre
‘A. Vercellone’ from January 2000 to December 2017. Patients
with a pre-transplant MGUS diagnosis (cases) were identified
and analysed separately. MGUS diagnosis was based on labora-
tory parameters, namely: serum electrophoresis, serum and uri-
nary immunofixation, free light kappa and lambda chain
determination, and, if available, bone marrow (BM) evaluation.
As policy of our Centre, patients with MGUS that is the cause of
ESRD are not eligible for KT. Indeed, all patients included in this
study had ESRD unrelated to the coexistent MGUS.
Data were collected from patient’s individual charts at the
time of KT and at 1-, 2-, 5- and 10-year follow-up, and at the last
follow-up visit in our post-transplant outpatient unit.
For each patient, we retrospectively reviewed sex, age, un-
derlying nephropathy, type of dialysis and its duration before
KT, previous transplant or immunosuppressive therapies, type
of transplant (deceased or living donor), immunosuppressive
therapy and post-transplant graft function [serum creatinine
(sCr) and 24 h proteinuria (Pto)]. Data regarding the haematolog-
ical disorder were collected as well, including monoclonal
gammopathy isotype, time of onset before KT, follow-up and
occurrence of post-transplant haematological progression.
Follow-up ended in May 2018.
A matched cohort analysis was performed considering a se-
lected population of patients with similar baseline characteris-
tics at KT (age at transplant, sex, type of dialysis, graft function
at discharge) without pre-transplant oncohaematological disor-
ders. A comparative analysis among MGUS isotypes was per-
formed as well.
Primary outcomes were graft and patient survival.
Secondary endpoints were causes of graft failure and patient
death as well as the occurrence of allograft rejection, secondary
neoplastic diseases and infectious complications.
Considering the high number of control patients, an adjunc-
tive analysis adopting a selected cohort of controls (ratio of
MGUS:controls, 1:2) matched for recipient age, gender, number of
transplantation and transplant period was also conducted in or-
der to reduce the bias due to potentially confounding variables.
This study was performed in adherence with the last version of
the Helsinki Declaration and with the Principles of the Declaration
of Istanbul on Organ Trafficking and Transplant Tourism.
Statistical methods
Discrete data were described as percentages and analysed with
Pearson Chi-squared test or for small samples, Fisher’s exact
test. Continuous variables were described as median (min–
max). Mann–Whitney and Kruskal–Wallis test were used when
appropriate. Cumulative graft and patient survival were ana-
lysed by Kaplan–Meier (KM) curves and log-rank test. According
to the KM model only independent events were included (i.e.
KTs>1 were excluded).
An adjunctive analysis was carried out adopting a manually
selected cohort of controls. The matching ratio was 1:2 and the
considered variables included recipient age and gender, number
of transplantation and transplant period. Statistical analyses
were performed using SPSS software, version 22 (SPSS, Inc.,
Chicago IL, USA, version 25.00). Significance level for all tests
was set at P< 0.05.
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RESULTS
Population characteristics at baseline (cases and
controls)
Between 1 January 2000 and 31 December 2017, 2034 KTs were
performed in 1965 patients at our centre; MGUS was present at
the time of KT in 65 patients (3.2%); it was not the cause of ESRD
in any case. Heavy and light chain isotypes were as it follows:
28/65 (43.1%) immunoglobulin G (IgG) kappa, 15/65 (23.1%) IgG
lambda, 5/65 (7.7%) IgA kappa, 1/65 (1.5%) IgA lambda, 2/65
(3.1%) IgM kappa and 2/65 (3.1%) IgM lambda; 1 patient had
biclonal gammopathy (IgG kappa and IgM lambda); in 13 cases
pre-transplant MGUS isotype was unknown. Urinary immuno-
fixation was negative in 46.2%; only 12 patients had an altered
kappa/lambda ratio; IgG, IgA and IgM levels were normal in
most cases (55.4%, 64.6% and 55.4%, respectively). A pre-
transplant BM biopsy was performed in 26 patients (38.2%). All
patients had regular haematological evaluations and all MGUS
patients were placed in the KT list following a thorough multi-
disciplinary re-assessment. Median time between MGUS diag-
nosis and KT was 60 (1–300) months; all patients showed stable
monoclonal peak during the follow-up period before KT.
The control group includes 1079 KTs performed at our
Centre between 2003 and 2013. Patient characteristics and im-
munosuppressive regimens at KT are summarized in Table 1:
there were no differences in sex, age at KT, main underlying ne-
phropathies and prevalence of patients on haemodialysis (HD)
between the two groups. There was a significantly higher preva-
lence of previous KT in cases (23%) compared with controls
(13.3%) (P< 0.05).
NS: not significant
Immunosuppressive therapy was tailored on donor and re-
cipient characteristics: basiliximab was used as induction in
89.5% cases and 94.3% controls in association with a calcineurin
inhibitor (CNI) -based regimen (97% of cases and 91.5% of con-
trols). There was a higher use of mTOR inhibitors in cases
(30.3%) than in controls (14.7%) (P¼ 0.001). Median sCr and Pto at
discharge were similar between groups: 1.9 mg/dL (0.87–7.5) and
0.3 g/24 h (0.1–3) in cases, and 1.88 mg/dL (0.5–8.1) and 0.36 g/24 h
(0–12) in controls, respectively.
Graft and patient survival, post-transplant complica-
tions (cases versus controls)
Median follow-up time was 3.5 years (0–14) in cases and
8.3 years (0–14.9) in controls.
Functional data during follow-up were similar between
groups. No differences were found in rates of allograft rejection
(10.8% in cases versus 15.6% in controls, P¼ 0.59) and post-
transplant neoplasia (16.7% in cases and 21.7% in controls,
P¼ 0.33). Incidence of infectious complications was significantly
higher in control group (69.8 versus 56.1, P¼ 0.019) (Table 2).
No differences were found between the two groups in graft
and patient survival (Figure 1 and Table 2): overall, 8/65
cases and 228/1079 controls had graft loss (P¼ 0.25); 7/65 cases
and 204/1079 controls died (P¼ 0.17). Among MGUS cases, three
patients died due to severe infectious complication, one died
from cardiovascular accident, one from respiratory distress and
one from hepatic failure; cause of death was unknown for the
last fatal event. Among controls, the main causes of death were
infectious diseases (14.2%) and cardiovascular accident (12.3%).
Graft and patient survival were also similar in the adjunctive
analysis with manually selected control cohort (Supplementary
data, Figures S1 and S2).
Table 3 summarizes haematological parameters at diagnosis
and during follow-up in the 65 patients with MGUS at KT. No pa-
tient showed MGUS progression and in 19 patients (29.2%) the
monoclonal component disappeared after KT. In many patients,
no specific evaluation of MGUS was performed during post-
transplant follow-up at definite time points.
MGUS isotype did not influence graft and patient survival
(Figure 2a and b).
DISCUSSION
In this matched cohort study, we investigate the role of MGUS
on patient and graft survival. Our findings demonstrate the ab-
sence of a direct effect of MGUS on both patients and kidney
survival, suggesting that subjects with MGUS may undergo KT
without significantly increased risks of complications.
MGUS is defined by the presence of a serum monoclonal pro-
tein (IgG, IgM, IgA, IgD, with kappa or lambda light chain) in an
abnormal but small concentration (3 g/dL), along with <10%
plasma cells infiltration in BM (when determined), a small
amount or absence of urinary light chains, and no clinical organ
damage. In particular, MGUS does not show the typical multiple
myeloma (MM) signs, included under the term CRAB, namely
hypercalcaemia, renal failure, anaemia, lytic bone lesions. A
small percentage of MGUS patients (3%) have indeed bi-clonal
rather than monoclonal gammopathy. MGUS is typically
detected as an incidental finding when patients undergo a pro-
tein electrophoresis as part of a routine evaluation or during di-
agnostic procedures for a wide variety of clinical symptoms and
disorders. MGUS frequency is quite variable, depending on the
strength of the employed screening test and in general MGUS
may occur in >3% of the general Caucasian population over the
age of 50 years, with an incidence slowly increasing with age [3,
13]. It is usually considered as a benign condition, but it can also
progress to MM, amyloidosis, macroglobulinaemia, light chain
deposition disease or lymphoplasmocytic cell proliferative dis-
ease, with a progression rate of 1–1.5%/year in the absence of
immunosuppression. Isotype and serum M-component concen-
tration are considered as the most important risk factors for
progression to a malignant disease [3, 4, 14, 15]. More recently,
the degree of immunoparesis, i.e. the reduction of uninvolved
immunoglobulins below lower level of normal, has been
reported as a relevant prognostic factor [16].
MGUS represents nowadays one of the most frequent onco-
haematological problem that must be dealt with while evaluat-
ing patients for KT. The main issue raised in case of MGUS
detection is the risk of progression towards patent lymphoproli-
ferative disorder as a consequence of the immunosuppressive
post-KT therapy. Furthermore, the influence of the monoclonal
gammopathy on KT outcome, in terms of both graft and patient
survival and risk of post-transplant complication, has not been
fully addressed.
In 2012, the International Kidney and Monoclonal
Gammopathy Research Group (IKMG) introduced the new ex-
pression ‘monoclonal gammopathy of renal significance’
(MGRS) to describe cases that would otherwise meet the criteria
for MGUS, but demonstrate renal insufficiency directly related
to the presence of monoclonal immunoglobulin deposits in the
kidney proved by immunofluorescence [17]. The IKMG met
again in April 2017 and redefined MGRS as any B-cell or plasma
cell clonal lymphoproliferation that does not cause tumour
complications or meet any current haematological criteria for
specific therapy and is associated with one or more kidney
lesions. These latter can be induced either by monoclonal Ig
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deposition in renal tissue or by its activity as autoantibody [18,
19]. This definition includes many different renal diseases such
as renal amyloidosis, fibrillar glomerulopathy, immunotactoid
glomerulopathy, cryoglobulinaemic glomerulonephritis Types I
and II, monoclonal immunoglobulin deposition disease, glomer-
ulonephritis associated with monoclonal immunoglobulin (pro-
liferative, membranoproliferative, membranous, C3 nephritis
and C4 dense deposit disease), tubulopathies like light chain
Fanconi syndrome, and atypical haemolytic uraemic syndrome.
Besides an increased morbidity and mortality, MGRS is charac-
terized by a high risk of recurrence in the post-renal transplant
period and an improvement after any lymphoproliferative
treatment [19]. It is therefore crucial to correctly distinguish be-
tween patients with MGUS and CKD from other causes, and
patients with CKD due to renal involvement in the course of
MGRS in order to use pre-transplant-specific therapies to target
the responsible clone and possibly achieve a complete remis-
sion of the haematological disorder.
Based on the high recurrence risk reported in literature, as
policy at our Centre, patients with MGUS of renal significance
that determined the cause of ESRD are not eligible for KT unless
they reached a stable remission of the haematological disease
[20–23]. None of the cases described in the present work had
MGRS; however, 30% of them had an unknown diagnosis of




Men/women, n (%) 45 (69.2)/20 (30.8) 697 (64.6)/382 (35.4)
Age at KT, median, years 60 (29–79) 55.2 (19.3–79.5)
Underlying nephropathy
Diabetic nephropathy, n (%) 4 (6.2) 47 (4.4)
Nephroangiosclerosis, n (%) 5 (7.7) 122 (11.3)
Glomerulonephritis, n (%) 18 (27.7) 355 (32.9)
Tubulo-interstitial disease, n (%) 5 (7.7) 114 (10.6)
APKD, n (%) 8 (12.3) 163 (15.1)
Not known, n (%) 21 (32.3) 171 (15.8)
Urological disease, n (%) 2 (3.1) 0
Malformative disease, n (%) 2 (3.1) 13 (1.2)
Other, n (%) 0 94 (8.7)
Type of dialysis
HD, n (%) 48 (73.8) 834 (77.3)
PD, n (%) 8 (12.3) 245 (22.7)
HDþPD, n (%) 8 (12.3) NA
Preemptive, n (%) 1 (1.5) NA
Dialysis before KT, median, years 3 (0.5–22) NA
Previous KT, n (%) 15 (23) 143 (13.3)
Previous immunosuppressive therapies, % 29 (44.6) NA
Living/cadaveric donor, % 4 (6.2)/61 (93.8) NA
Induction immunosuppressive therapy
ATG, n (%) 2 (3) 5 (0.5)
Basiliximab, n (%) 58 (89.5) 1018 (94.3)
ATG þ basiliximab, n (%) 4 (6) 15 (1.4)
Daclizumab, n (%) 1 (1.5) 0
St only, n (%) 0 15 (1.4)
Not known, n (%) 0 26 (2.4)
Immunosuppression at discharge
CNI þMMF þ St, n (%) 52 (80) 688 (63.8)
CNI þ St, n (%) 6 (9.2) 228 (21.1)
CNI þmTOR inhibitor þ St, n (%) 5 (7.7) 50 (4.6)
CNI þ AZA, n (%) 0 0
mTOR inhibitor þMMF þ St, n (%) 2 (3.1) 24 (2.2)
St only, n (%) 0 0
CNI þ AZA þ St, n (%) 0 19 (1.8)
CNI þMMF, n (%) 0 1 (0.1)
CNI only, n (%) 0 1 (0.1)
MMF þ St, n (%) 0 13 (1.2)
mTOR inhibitor þ St, n (%) 0 1 (0.1)
NA, n (%) 0 54 (5)
sCr at discharge, median, mg/dL 1.9 (0.87–7.5) 1.88 (0.5–8.1)
Pto at discharge, median, g/24 h 0.3 (0.1–3) 0.36 (0–12)
APKD, autosominal-dominant polycystic kidney disease, PD, peritoneal dialysis; NA, not available; ATG, anti-thymocyte globulin; AZA, azathioprine; MMF, mycophe-
nolate mofetil; St, steroids.







niversity of Torino user on 25 Septem
ber 2020
ESRD, therefore it may not be possible to unequivocally exclude
the presence of MGUS of renal significance in some of our
patients. However, no recurrence of renal disease on the grafted
kidneys was recorded and this further argues against the
possible role of the coexisting MGUS on the development of re-
nal damages.
For patients with MGUS lacking any clear correlation be-
tween monoclonal gammopathy and renal failure, specific and
Table 2. Clinical and functional characteristics in patients with pre-transplant MGUS versus controls
Clinical variables
MGUS Controls
P-value(n¼ 65) (n¼ 1079)
Follow-up, median, years 3.5 (0–14) 8.3 (0–14.9) NS
sCr, median, mg/dL
At discharge (n) 1.9 (0.87–7.5) (64) 1.8 (0.5–8.1) (1038) NS
1 year (n) 1.6 (0.8–4.3) (57) 1.5 (0.6–6.5) (989) NS
2 years (n) 1.6 (0.7–4.6) (54) 1.5 (0.2–4.6) (943) NS
5 years (n) 1.6 (0.8–3) (29) 1.5 (0.6–5.9) (744) NS
10 years (n) 1.6 (1–3) (10) 1.4 (0.5–5.1) (267) NS
Last follow-up (n) 1.8 (0.7–9) (61) 1.7 (0–11.9) (1015) NS
Pto, median, g/24 h
At discharge (n) 0.3 (0.1–3) (61) 0.36 (0–12) (970) NS
1 year (n) 0.2 (0–4) (57) 0.2 (0–8.3) (949) NS
2 years (n) 0.2 (0–3.9) (53) 0.2 (0–10) (911) NS
5 years (n) 0.3 (0–2) (29) 0.2 (0–10) (727) NS
10 years (n) 0.3 (0.1–3.8) (10) 0.2 (0–18) (262) NS
Last follow-up (n) 0.3 (0–4.2) (57) 0.3 (0–18) (940) NS
Functioning grafts at the end of the follow-up, n (%) 56 (86.2) 851 (78.9) NS
Deaths, n (%) 7 (10.8) 204 (18.9) NS
Allograft rejection, n (%) 6 (9.3) 168 (15.6) NS
Cellular rejection, n (%) 2 (3.1) 81 (7.5) NS
Vascular rejection, n (%) 2 (3.1) 47 (4.4) NS
Cellular þ vascular rejection, n (%) 2 (3.1) 40 (3.7) NS
Infectious complications, n (%) 38 (58.7) 753 (69.8) <0.05
Post-KT neoplasia, n (%) 12 (18.5) 234 (21.7) NS
mTOR inhibitor during follow-up, n (%) 20 (30.3) 159 (14.7) <0.05
Table 3. Laboratory evaluations in MGUS patients during follow-up
Laboratory findings
Diagnosis Discharge First year Second year Fifth year Tenth year
(n¼ 65) (n¼65) (n¼ 57) (n¼ 54) (n¼ 29) (n¼ 10)
Monoclonal peak
Present/absent, n 65/0 10/12 24 /13 19/12 9/9 4/5
NA, n 0 43 20 23 11 1
Seric immunofixation
Positive/negative, n 51/9a 9/8 17/5 16/6 11/5 3/1
NA, n 5 48 35 32 13 6
Urinary immunofixation
Positive/negative, n 16/30 1/16 4/13 2/17 1/13 0/4
NA, n 19 48 40 35 15 6
kappa/lambda ratio
Increased, n 10 2 2 1 0 0
Reduced, n 2 0 0 0 1 1
Normal, n 10 5 7 8 6 3
NA, n 43 58 48 45 22 6
IgG MGUS, n 43 43 35 34 17 5
IgA/IgM reduction, n 13 11 2 0 0 0
NA, n 8 21 28 23 11 4
IgA MGUS, n 6 6 6 5 2 0
IgG/IgM reduction, n 1 0 0 0 0 0
NA, n 1 5 5 4 1 0
IgM MGUS 3 3 3 2 2 2
IgG/IgA reduction, n 1 2 1 0 0 0
NA, n 0 1 2 1 1 1
aIntended as first immunofixation test available with persistence of monoclonal peak in several electrophoresis.
NA: not available
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univocal recommendations or contraindications to perform KT
have not been established so far. Both the 2005 Canadian
Society Guidelines and the 2013 Caring for Australians with
Renal Impairment (CARI) Guidelines on recipient assessment
for KT did not recommend a specific waiting time for patients
with pre-existing MGUS [7, 8]. The European Renal Best Practice
Guidelines only focused on previous lymphomas without rec-
ommendations about other oncohaematological conditions [10].
The 2011 British Transplantation Society Guidelines focused in-
stead on previous post-transplant lymphoproliferative disease
(PTLD) [12]. Furthermore, no guideline contains indications
about examinations needed before KT to assess disease remis-
sion or non-progression in case of MGUS. Additional specific
tests are usually performed only in selected cases and when a
haematological consultation is requested. Indeed, also in our
series, only 39.4% of our MGUS patients underwent a deep ex-
amination including BM biopsy before KT. Thus, given the in-
creasingly documented presence of MGUS in the general
population and consequently in subjects requiring KT, as also
confirmed by our survey, specific recommendations for the
management of these patients in the setting of solid organ
transplant are warranted.
The significant higher prevalence of previous KT in cases
(23% versus 13.3%, P< 0.05) could be partly related to the high
prevalence of patients with MGUS developed after their first KT
(11/15). The incidence of MGUS after KT has been assessed in
few studies, with conflicting results: Passweg et al. showed a
5-year cumulative incidence of 10.7%, much higher than
expected for a group of similar age from the general population
[24], Cuéllar-Garcia et al. reported a 2.9% prevalence of the hae-
matologic disease after KT [25], while Bancu et al. only a 1.57%
prevalence [5], and Alfano et al. found an overall prevalence of
patients with stable MGUS after KT of 8.1% [26]. In these studies,
KT and its associated need for immunosuppressive therapies
seemed to act as predisposing factors for the development of
MGUS irrespective of patient’s age and gender.
Besides a few case reports and case series, there are limited
data in the literature regarding the long-term outcome of
patients with oncohaematological disease undergoing KT. Our
study offers insights on MGUS, with the observation in a signifi-
cant group of 65 patients with pre-existing MGUS and treated
with KT for ESRD. In the general population, MGUS has report-
edly a low progression rate, around 1–1.5%/year [15]. In our se-
ries, no patient showed a disease progression after KT,
regardless of the immunosuppression prophylaxis after KT and
type or concentration of serum monoclonal protein. Conflicting
results are reported in the literature. In particular, 4 out of 23
(17.4%) patients with pre-transplant MGUS developed post-
transplant smoldering MM and PTLD in the study by Naina et al.
[3], whereas in two other small series (nine patients each) with
pre-existing MGUS, only one post-transplant MM has been
reported [4, 5]. Lastly, a case report described the occurrence of
AL amyloidosis 10 years after KT and prolonged over-
immunosuppression in a patient with pre-existing MGUS [6]. All
authors concluded that patients with MGUS and ESRD should
not be excluded from KT, although a close post-transplant mon-
itoring is clearly recommended. However, no specific indica-
tions have been so far outlined regarding type and timing of
diagnostic examinations to be performed before and at given
intervals following KT.
A second issue of concern is the possible negative influence
of the co-existing of MGUS on transplant outcomes. Indeed, our
matched cohort study showed no differences in graft and pa-
tient survival between MGUS group and controls, as also
FIGURE 1: Death-censored survival from the time of KT of patients with MGUS and matched population with a negative history (controls). No significant difference in
survival was noted (P¼0.574).
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confirmed by the adjunctive analysis only considering the se-
lected cohort of controls matched for recipient age, gender,
number of transplantation and transplant period. Furthermore,
incidence of main post-transplant complications was analogous
between the two groups. An increased use of mTOR inhibitors
as immunosuppressant therapy was seen in our MGUS series
compared with controls (30.3% versus 14.7%, respectively). This
can be simply explained by the cautiously use of strong immu-
nosuppressive drugs, as also reflected by the lower infectious
complications in the MGUS compared with the control group
(56.1% versus 69.8%). Moreover, the anti-proliferative effect of
mTOR inhibitors is well known and various studies support its
use in the context of post-transplant solid neoplasia, in particu-
lar non-melanoma skin cancer. However, evidence favouring
the use of mTOR inhibitors in oncohaematological disorders,
specifically in co-existing MGUS, are limited [27, 28]. Indeed,
specific recommendations on the ideal immunosuppressive
regimens to be used in patients with MGUS or other haemato-
logical disorders at potentially increased risk of post-transplant
complications are lacking. Patients with pre-transplant MGUS
are likely to require specific immunosuppressive treatment,
both in induction and in maintenance. Large registry-based
studies will allow definition of the optimal immunosuppressive
strategy for MGUS and other haematological disorders coexist-
ing in patient candidates to KT for ESRD.
In summary, this study addresses the issue of the coexis-
tence of haematological abnormalities, namely the MGUS disor-
ders, in patients undergoing KT for ESRD. To our knowledge,
this is indeed the largest series reporting KT and haematological
outcomes in patients with pre-transplant MGUS, including a
comparative analysis with a control population with similar
characteristics and post-transplant management. The study
confirms the importance of specific and multidisciplinary
approaches for the management of patients with co-existing
FIGURE 2: Overall survival (a) and death-censored survival (b) from the time of KT according to MGUS isotypes. No significant difference in survival was noted (P¼0.731
and 0.44, respectively).
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haematological abnormalities and ESRD. Moreover, our observa-
tions give further support to the concept that patients with pre-
existing MGUS may undergo KT, without significantly increased
risks of complications, provided that appropriate diagnostic
procedures are carefully followed. Additional multidisciplinary
studies will help to standardize pre- and post-transplant moni-
toring protocols for the best management of patients with coex-
isting MGUS and need of KT.
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